<DOC>
	<DOCNO>NCT02474186</DOCNO>
	<brief_summary>1 . To induce immunity-mediated tumor response outside radiation field ( abscopal effect ) chemo-radiation metastatic site metastatic breast cancer patient . 2 . To monitor induction T cell response . 3 . To explore role PET scan assess tumor responses/abscopal effect .</brief_summary>
	<brief_title>Phase II Study Solid Metastatic Tumors</brief_title>
	<detailed_description>1 . To induce immunity-mediated tumor response outside radiation field ( abscopal effect ) chemo-radiation metastatic site pilot study metastatic breast metastatic solid tumor . 2 . To monitor induction T cell response patient metastatic breast cancer . 3 . To explore role PET scan assess tumor response/abscopal effect . Eligible woman metastatic breast cancer patient metastatic solid tumor achieve stable disease disease progression systemic therapy least three separate measurable site disease . Extent metastatic disease record CT PET scan . Radiation give systemic therapy one lesion , 35 Gy ten fraction two week interval , conformally maximally spare normal tissue . GM-CSF treatment give daily fourteen day . At day 22 radiation re-started radiation dose deliver second metastatic site , GM-CSF . Abscopal response evaluate assess clinical PET response non-irradiated measurable metastatic site . A Phase II clinical trial base optimum two-stage Phase II Simon design use conduct pilot study . Ten patient treated Stage one ; abscopal response , trial terminate . If one abscopal responses Stage One , trial proceed enroll additional 19 patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients histologically confirm breast cancer cancer persistent metastatic recurrent metastatic . Patients history treatment prior malignancy eligible , provide remain diseasefree &gt; 2 year initial treatment , treat nonmelanoma skin cancer , situ cervical cancer . Patients must least 3 distinct measurable metastatic site least 1 cm large large diameter . Age &gt; 18 year . ECOG performance status &lt; 2 ( Karnofsky &gt; 50 % ) . Life expectancy &gt; 3 month . Patients immunotherapy within 4 week prior enter study . Patients prior allergic reaction GMCSF Patients steroid therapy immunosuppressive therapy . Patients undergo therapy investigational agent . Patients know brain metastasis include clinical trial brain lesion eligible target non target lesion . Uncontrolled intercurrent illness include , limited ongoing active infection , symptomatic congestive heart failure , myocardial infarction within past 6 month , unstable angina pectoris , unstable cardiac arrhythmia require assessment clinical intervention .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>breast</keyword>
	<keyword>cancer</keyword>
	<keyword>metastatic</keyword>
	<keyword>breast cancer</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>radiation</keyword>
	<keyword>radiotherapy</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>abscopal</keyword>
	<keyword>abscopal effect</keyword>
	<keyword>T-cell</keyword>
	<keyword>GM-CSF</keyword>
	<keyword>anti-tumor</keyword>
	<keyword>immune</keyword>
	<keyword>immune response</keyword>
	<keyword>capecitabine</keyword>
	<keyword>xeloda</keyword>
	<keyword>taxol</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>solid metastatic tumor</keyword>
</DOC>